Eli Lilly — Oct 30, 2024 release

Based on these changes, EPS guidance has been lowered to the ranges of $12.05 to $12.55 on a reported basis and $13.02 to $13.52 on a non-GAAP basis. The company's 2024 financial guidance reflects adjustments shown in the reconciliation table below. 10 2024 Guidance (1) Earnings per share (reported) $12.05 to $12.55 Amortization of intangible assets .49 Asset impairment, restructuring, and other special charges .45 Net losses on investments in equity securities .03 Earnings per share (non-GAAP) $13.02 to $13.52 Numbers may not add due to rounding (1) Reported and Non-GAAP EPS guidance both include $3.33 of acquired IPR&D charges incurred through Q3 2024. The following table summarizes the company's 2024 financial guidance: 2024 Guidance (1) Prior Updated (3) Revenue $45.4 to $46.6 billion $45.4 to $46.0 billion (Gross Margin - OPEX (2) ) / Revenue: (reported) 36% to 38% unchanged (non-GAAP) 37% to 39% unchanged Other Income/(Expense) (reported) ($525) to ($425) million ($425) to ($325) million Other Income/(Expense) (non-GAAP) ($400) to ($300) million unchanged Tax Rate Approx. 15% Approx. 17% Earnings per Share (reported) $15.10 to $15.60 $12.05 to $12.55 Earnings per Share (non-GAAP) $16.10 to $16.60 $13.02 to $13.52 (1) Non-GAAP guidance reflects adjustments presented in the earnings per share reconciliation table above. (2) OPEX is defined as the sum of research and development expenses and marketing, selling and administrative expenses. (3) Guidance includes acquired IPR&D charges throug